DelveInsight’s “Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acute Respiratory Distress Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Respiratory Distress Syndrome Market Forecast
Some of the key facts of the Acute Respiratory Distress Syndrome Market Report:
- The Acute Respiratory Distress Syndrome market size was valued approximately USD 1,065 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to DelveInsight, the total number of ARDS incidents in the 7MM was estimated to reach 956.803 in 2021
- Studies indicate that there are more occurrences of Acute Respiratory Distress Syndrome in the US, with an expected 604,103 cases in the year 2021
- In February 2021, In a statement, Athersys stated that it had collaborated with HEALIOS. The goal of the cooperation agreement is to reaffirm the parties’ shared dedication to the cooperative growth of MultiStem in Japan
- In March 2021, SIRS Therapeutics and F4 Pharma signed a licensing and collaboration agreement with Partner Therapeutics to help with the development of FX-06. There are several potential uses for this synthetic peptide
- Key Acute Respiratory Distress Syndrome Companies: Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others
- Key Acute Respiratory Distress Syndrome Therapies: Traumakine, BIO-11006, MultiStem, Solnatide, VERU-111, Tradipitant, FP-025, HLCM051(MultiStem), and others
- The Acute Respiratory Distress Syndrome epidemiology based on gender analyze that the percentage of cases of Acute Respiratory Distress Syndrome (ARDS) are equal in both the genders
- The Acute Respiratory Distress Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Respiratory Distress Syndrome pipeline products will significantly revolutionize the Acute Respiratory Distress Syndrome market dynamics.
Acute Respiratory Distress Syndrome Overview
Acute respiratory distress syndrome (ARDS) is a condition that affects critically ill people and progresses quickly.Breathing becomes difficult or impossible due to fluid leakage into the lungs, which is the main consequence of ARDS.
Get a Free sample for the Acute Respiratory Distress Syndrome Market Report
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market
Acute Respiratory Distress Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Acute Respiratory Distress Syndrome Epidemiology Segmentation:
The Acute Respiratory Distress Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Acute Respiratory Distress Syndrome
- Prevalent Cases of Acute Respiratory Distress Syndrome by severity
- Gender-specific Prevalence of Acute Respiratory Distress Syndrome
- Diagnosed Cases of Episodic and Chronic Acute Respiratory Distress Syndrome
Download the report to understand which factors are driving Acute Respiratory Distress Syndrome epidemiology trends @ Acute Respiratory Distress Syndrome Epidemiology Forecast
Acute Respiratory Distress Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome market or expected to get launched during the study period. The analysis covers Acute Respiratory Distress Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Respiratory Distress Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Acute Respiratory Distress Syndrome Therapies and Key Companies
- Traumakine: Faron Pharmaceuticals
- BIO-11006: BioMarck Pharmaceuticals
- MultiStem: Athersys
- Solnatide: Apeptico Forschung und Entwicklung GmbH
Discover more about therapies set to grab major Acute Respiratory Distress Syndrome market share @ Acute Respiratory Distress Syndrome Treatment Market
Acute Respiratory Distress Syndrome Market Drivers
- Increasing R&D Activities
- Increasing incidence of ARDS
- Non-competitive Landscape
Acute Respiratory Distress Syndrome Market Barriers
- Lack of awareness about the disease
- Misdiagnosis of ARDS
- Mechanical Ventilation for Management
- Failure of Trials for ARDS
Scope of the Acute Respiratory Distress Syndrome Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Acute Respiratory Distress Syndrome Companies: Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others
- Key Acute Respiratory Distress Syndrome Therapies: Traumakine, BIO-11006, MultiStem, Solnatide, VERU-111, Tradipitant, FP-025, HLCM051(MultiStem), and others
- Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
- Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Acute Respiratory Distress Syndrome Unmet Needs, KOL’s views, Analyst’s views, Acute Respiratory Distress Syndrome Market Access and Reimbursement
To know more about Acute Respiratory Distress Syndrome companies working in the treatment market, visit @ Acute Respiratory Distress Syndrome Clinical Trials and Therapeutic Assessment
Table of Contents
1. Acute Respiratory Distress Syndrome Market Report Introduction
2. Executive Summary for Acute Respiratory Distress Syndrome
3. SWOT analysis of Acute Respiratory Distress Syndrome
4. Acute Respiratory Distress Syndrome Patient Share (%) Overview at a Glance
5. Acute Respiratory Distress Syndrome Market Overview at a Glance
6. Acute Respiratory Distress Syndrome Disease Background and Overview
7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Respiratory Distress Syndrome
9. Acute Respiratory Distress Syndrome Current Treatment and Medical Practices
10. Acute Respiratory Distress Syndrome Unmet Needs
11. Acute Respiratory Distress Syndrome Emerging Therapies
12. Acute Respiratory Distress Syndrome Market Outlook
13. Country-Wise Acute Respiratory Distress Syndrome Market Analysis (2019–2032)
14. Acute Respiratory Distress Syndrome Market Access and Reimbursement of Therapies
15. Acute Respiratory Distress Syndrome Market Drivers
16. Acute Respiratory Distress Syndrome Market Barriers
17. Acute Respiratory Distress Syndrome Appendix
18. Acute Respiratory Distress Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services